Drug Profile
Sapanisertib - Takeda Oncology
Alternative Names: CB-228; HY-13328; INK-128; MLN-0128; TAK-228Latest Information Update: 22 Mar 2024
Price :
$50
*
At a glance
- Originator Intellikine
- Developer Calithera Biosciences; Dana-Farber Cancer Institute; European Network for Translational Research in Ovarian Cancer (EUTROC); M. D. Anderson Cancer Center; National Cancer Institute (USA); Stanford University School of Medicine; Takeda; Takeda Oncology
- Class Antineoplastics; Benzoxazoles; Pyrazolones; Pyrimidines; Small molecules
- Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Bladder cancer; Endometrial cancer; Fallopian tube cancer; Glioblastoma; Neuroendocrine tumours; Ovarian cancer; Peritoneal cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Soft tissue sarcoma; Thyroid cancer; Urogenital cancer
- Phase I/II Liver cancer; Merkel cell carcinoma; Sarcoma
- Preclinical Leukaemia
- No development reported Cancer; Non-small cell lung cancer; Solid tumours
- Discontinued HER2 negative breast cancer; Multiple myeloma; Prostate cancer; Renal cell carcinoma; Triple negative breast cancer; Waldenstrom's macroglobulinaemia
Most Recent Events
- 08 Mar 2024 National Cancer Institute reinitiates a phase I trial for non-small cell lung cancer (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT04250545)
- 28 Jul 2023 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
- 28 Jun 2023 No recent reports of development identified for phase-I development in Cancer(Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (PO)